The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia

  1. García-Tuñón, I.
  2. Hernández-Sánchez, M.
  3. Ordoñez, J.L.
  4. Alonso-Pérez, V.
  5. Álamo-Quijada, M.
  6. Benito, R.
  7. Guerrero, C.
  8. Hernández-Rivas, J.M.
  9. Sánchez-Martín, M.
Zeitschrift:
Oncotarget

ISSN: 1949-2553

Datum der Publikation: 2017

Ausgabe: 8

Nummer: 16

Seiten: 26027-26040

Art: Artikel

DOI: 10.18632/ONCOTARGET.15215 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus